2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2156

Persistent Arthralgia Following Chikungunya Fever
Abstract Number: 2008

Personalized Risk Education for Rheumatoid Arthritis Improves Self-Perceived Risk Accuracy and Risk Factor Knowledge in First-Degree Relatives
Abstract Number: 2771

PET-CT Imaging and Association of Ferritin Autoantibodies in Polymyalgia Rheumatica
Abstract Number: 2364

PET-CT Imaging of Joints: A Quantitative Tool for Developing Novel Anti-Inflammatory Drugs
Abstract Number: 797

PET/CT for the Diagnosis of Giant Cell Arteritis: A Prospective Study
Abstract Number: 1998

pGALS Training Increases Kenyan Pediatric Residents’ Confidence in Performing a Musculoskeletal Exam
Abstract Number: 2444

Pharmacist-Developed Letters May Enhance Success in Obtaining Insurer Approval for Off-Label Use of Biologics
Abstract Number: 1945

Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Patients with Systemic Lupus Erythematosus
Abstract Number: 1504

Pharmacokinetic Equivalence of ABP 501 Relative to Adalimumab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects
Abstract Number: 1478

Pharmacokinetics, Bioavailability and Safety of a Modified-Release Once-Daily Formulation of Tofacitinib in Healthy Volunteers
Abstract Number: 677

Pharmacokinetics, Safety, and Biological Activity of Intravenously or Subcutaneously Administered Tabalumab in Subjects with Rheumatoid Arthritis or Systemic Lupus Erythematosus
Abstract Number: 282

Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate. Consolidated Baseline Characteristics from Pharmachild and Other National Registries
Abstract Number: 1481

Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug-Drug Interactions
Abstract Number: 946

Phase 1 Study of Immunotherapy Using Autoantigen-Loaded Dendritic Cells in Patients with Anti-Citrullinated Peptide Antigen Positive Rheumatoid Arthritis
Abstract Number: 923

Phenotypes of Osteoarthritis-Related Knee Pain and Their Transitions over Time: The Osteoarthritis Initiative

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].